View in EDS HTML Full Text PDF Full Text

First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.

Saved in:
Bibliographic Details
Title: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
Authors: Shimizu T; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan., Powderly J; Carolina BioOncology Institute, Huntersville, NC, United States., Abdul Razak A; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada., LoRusso P; Yale Cancer Center, Yale University, New Haven, CT, United States., Miller KD; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States., Kao S; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia., Kongpachith S; AbbVie Bay Area, South San Francisco, CA, United States., Tribouley C; AbbVie Bay Area, South San Francisco, CA, United States., Graham M; AbbVie Bay Area, South San Francisco, CA, United States., Stoll B; AbbVie Bay Area, South San Francisco, CA, United States., Patel M; AbbVie Bay Area, South San Francisco, CA, United States., Sahtout M; AbbVie Bay Area, South San Francisco, CA, United States., Blaney M; AbbVie Bay Area, South San Francisco, CA, United States., Leibman R; AbbVie Bay Area, South San Francisco, CA, United States., Golan T; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel., Tolcher A; New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States.
Source: Frontiers in oncology [Front Oncol] 2024 Oct 29; Vol. 14, pp. 1376551. Date of Electronic Publication: 2024 Oct 29 (Print Publication: 2024).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39534099
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shimizu+T%22">Shimizu T</searchLink>; Department of Experimental Therapeutics, National Cancer Center Hospital, Tokyo, Japan.; Department of New Experimental Therapeutics and International Cancer New Drug Development Center, Kansai Medical University Hospital, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Powderly+J%22">Powderly J</searchLink>; Carolina BioOncology Institute, Huntersville, NC, United States.<br /><searchLink fieldCode="AU" term="%22Abdul+Razak+A%22">Abdul Razak A</searchLink>; Cancer Clinical Research Unit (CCRU), Princess Margaret Cancer Centre, Toronto, ON, Canada.<br /><searchLink fieldCode="AU" term="%22LoRusso+P%22">LoRusso P</searchLink>; Yale Cancer Center, Yale University, New Haven, CT, United States.<br /><searchLink fieldCode="AU" term="%22Miller+KD%22">Miller KD</searchLink>; Department of Medicine, Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, IN, United States.<br /><searchLink fieldCode="AU" term="%22Kao+S%22">Kao S</searchLink>; Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, NSW, Australia.<br /><searchLink fieldCode="AU" term="%22Kongpachith+S%22">Kongpachith S</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Tribouley+C%22">Tribouley C</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Graham+M%22">Graham M</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Stoll+B%22">Stoll B</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Patel+M%22">Patel M</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Sahtout+M%22">Sahtout M</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Blaney+M%22">Blaney M</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Leibman+R%22">Leibman R</searchLink>; AbbVie Bay Area, South San Francisco, CA, United States.<br /><searchLink fieldCode="AU" term="%22Golan+T%22">Golan T</searchLink>; Institute of Oncology, Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel.; Oncology Institute, Sheba Medical Center at Tel-Hashomer, Tel Aviv University, Tel Aviv, Israel.<br /><searchLink fieldCode="AU" term="%22Tolcher+A%22">Tolcher A</searchLink>; New Experimental Therapeutics (NEXT) Oncology, San Antonio, TX, United States.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22101568867%22">Frontiers in oncology</searchLink> [Front Oncol] 2024 Oct 29; Vol. 14, pp. 1376551. <i>Date of Electronic Publication: </i>2024 Oct 29 (<i>Print Publication: </i>2024).
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Frontiers+Research+Foundation]%22">Frontiers Research Foundation] </searchLink><i>Country of Publication: </i>Switzerland <i>NLM ID: </i>101568867 <i>Publication Model: </i>eCollection <i>Cited Medium: </i>Print <i>ISSN: </i>2234-943X (Print) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%222234943X%22">2234943X </searchLink><i>NLM ISO Abbreviation: </i>Front Oncol <i>Subsets: </i>PubMed not MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39534099
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.3389/fonc.2024.1376551
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 1376551
    Titles:
      – TitleFull: First-in-human phase 1 dose-escalation results with livmoniplimab, an antibody targeting the GARP:TGF-ß1 complex, as monotherapy and in combination with the anti-PD-1 antibody budigalimab in patients with advanced solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shimizu T
      – PersonEntity:
          Name:
            NameFull: Powderly J
      – PersonEntity:
          Name:
            NameFull: Abdul Razak A
      – PersonEntity:
          Name:
            NameFull: LoRusso P
      – PersonEntity:
          Name:
            NameFull: Miller KD
      – PersonEntity:
          Name:
            NameFull: Kao S
      – PersonEntity:
          Name:
            NameFull: Kongpachith S
      – PersonEntity:
          Name:
            NameFull: Tribouley C
      – PersonEntity:
          Name:
            NameFull: Graham M
      – PersonEntity:
          Name:
            NameFull: Stoll B
      – PersonEntity:
          Name:
            NameFull: Patel M
      – PersonEntity:
          Name:
            NameFull: Sahtout M
      – PersonEntity:
          Name:
            NameFull: Blaney M
      – PersonEntity:
          Name:
            NameFull: Leibman R
      – PersonEntity:
          Name:
            NameFull: Golan T
      – PersonEntity:
          Name:
            NameFull: Tolcher A
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 29
              M: 10
              Text: 2024 Oct 29
              Type: published
              Y: 2024
          Identifiers:
            – Type: issn-print
              Value: 2234-943X
          Numbering:
            – Type: volume
              Value: 14
          Titles:
            – TitleFull: Frontiers in oncology
              Type: main
ResultId 1